Click here for flash
Register for Updates
Be notified when new content and features are added to CLLPerspectives.com. Go
CLL Perspectives features the latest news and clinical information about CLL, brought to you in part by our advisory board of leading CLL experts. Access up-to-date clinical reviews, download educational resources and hear from our advisors on key topics in CLL. Our goal is to help you achieve better outcomes for your CLL patients. Learn more about us.
Featured Perspectives

Farrukh Awan, MD, MS
John C. Byrd, MD

Staging and Prognostic Factors in CLL
Thus far, no study has shown a survival advantage with early treatment in patients with CLL and a subset of CLL patients will never require therapy. This has led to the research efforts in CLL that have identified several specific biologic or clinical prognostic factors that predict time to progression and overall survival. With these recent...

Constantine S. Tam, MB, BS Susan Lerner, MS
Michael J. Keating, MB, BS

New Prognostic Markers in CLL
The recent proliferation of new "prognostic markers" in chronic lymphocytic leukemia (CLL) has provided valuable insights into the biology of the disease.1 In particular, significant survival differences when patients are classified by immunoglobulin heavy chain variable region (IGVH) mutation status2,3, fluorescent in-situ hybridization (FISH)...
Read more Read more

News & Commentary - provided by Medworm

 
NICE Recommends Leukaemia Drug For NHS Use

Rituximab (MabThera, Roche Products) will now be routinely available to certain NHS patients with chronic lymphocytic leukaemia, thanks to final guidance published today (28 July). The NHS has three months to begin implementing this new guidance... (Source: Health News from Medical News Today)

MedWorm Message: Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.

Source: Health News from Medical News Today - Wednesday, July 28, 2010
Rituximab confirmed as cost effective for CLL in Romania

(Source: PharmacoEconomics and Outcomes News)

Source: PharmacoEconomics and Outcomes News - Sunday, July 25, 2010
Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression

Authors: Joan H Admirand, Ronald J Knoblock, Kevin R Coombes, Constantine Tam, Ellen J Schlette, William G Wierda, Alessandra Ferrajoli, Susan O'Brien, Michael J Keating, Rajyalakshmi Luthra, L Jeffrey Medeiros & Lynne V Abruzzo (Source: Modern Pathology AOP)

Source: Modern Pathology AOP - Thursday, July 22, 2010
Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms

In conclusion, the del(14q) is a rare recurrent alteration in diverse mature B-cell neoplasms, shows variable size but distinct clustering of breakpoints, and is associated with short time to treatment. (Source: British Journal of Haematology)

Source: British Journal of Haematology - Wednesday, July 21, 2010
Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients

Authors: M Russo, C Spagnuolo, S Volpe, A Mupo, I Tedesco & G-L Russo (Source: British Journal of Cancer AOP)

Source: British Journal of Cancer AOP - Monday, July 19, 2010